In line with the data shown in two preclinical models most recently, we could demonstrate the efficacy of the combined therapeutic concept consisting of radiochemotherapy, TKD/IL-2-activated NK cells and PD-1 inhibition in a patient with membrane Hsp70 positive stage IIIb NSCLC. This evidence concerns the gene IL2 and non-small cell lung carcinoma.